{
    "title": "Merck osteoporosis drug passes trial, but side effects hover",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-2757043/Merck-osteoporosis-drug-passes-trial-effects-hover.html",
    "date": "2014-09-15",
    "keywords": [
        "osteoporosis",
        "trial",
        "odanacatib",
        "drug",
        "side",
        "placebo",
        "gmt",
        "september",
        "ransdell",
        "approval",
        "year",
        "thighbone",
        "risk",
        "merck",
        "incidence",
        "type",
        "group",
        "research",
        "treatment",
        "safety",
        "marketing",
        "email",
        "co",
        "pill",
        "blockbuster",
        "product",
        "industry",
        "hip",
        "spine",
        "mondaythe",
        "disease",
        "rate",
        "patient",
        "death",
        "fibrillation",
        "heartbeat",
        "none",
        "femur",
        "class",
        "fosamax",
        "kaufman",
        "official",
        "form",
        "trauma",
        "contrast",
        "condition",
        "profile",
        "concern",
        "capital",
        "analyst",
        "arfaei",
        "note",
        "risksarfaei",
        "latestage",
        "effectiveness",
        "street",
        "half",
        "company",
        "filing",
        "extension",
        "studykaufman",
        "application",
        "longterm",
        "benefit",
        "odanacatibodanacatib",
        "cathepsin",
        "enzyme",
        "process",
        "bonemerck",
        "monday",
        "york",
        "stock",
        "exchange",
        "reporting",
        "pierson",
        "meredith",
        "orr"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}